Skip to Content

Barinthus Biotherapeutics PLC ADR BRNS

Morningstar Rating
$2.50 +0.07 (2.93%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BRNS is trading at a 70% discount.
Price
$2.60
Fair Value
$3.95
Uncertainty
Extreme
1-Star Price
$658.28
5-Star Price
$3.78
Economic Moat
Kwzw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BRNS is a good fit for your portfolio.

Trading Information

Previous Close Price
$2.43
Day Range
$2.402.60
52-Week Range
$1.645.10
Bid/Ask
$1.02 / $2.60
Market Cap
$97.30 Mil
Volume/Avg
6,864 / 22,708

Key Statistics

Price/Earnings (Normalized)
Price/Sales
119.66
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
130

Valuation

Metric
BRNS
Price/Earnings (Normalized)
Price/Book Value
0.52
Price/Sales
119.66
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
BRNS
Quick Ratio
12.34
Current Ratio
12.45
Interest Coverage
−2,834.68
Quick Ratio
BRNS

Profitability

Metric
BRNS
Return on Assets (Normalized)
−25.10%
Return on Equity (Normalized)
−28.54%
Return on Invested Capital (Normalized)
−28.26%
Return on Assets
BRNS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQkrdmsyhvXgwyg$554.7 Bil
VRTX
Vertex Pharmaceuticals IncQdcpbbpCtbpwwr$102.7 Bil
REGN
Regeneron Pharmaceuticals IncGgfwcfgfXmgkqm$97.8 Bil
MRNA
Moderna IncTlqshvrThdhj$41.3 Bil
ARGX
argenx SE ADRWdwxpfzQlh$22.3 Bil
BNTX
BioNTech SE ADRPrfmxtwtTck$21.0 Bil
ALNY
Alnylam Pharmaceuticals IncFwqmqlfsFhvfw$18.2 Bil
BMRN
Biomarin Pharmaceutical IncPsnbvblgHytwzvr$15.4 Bil
RPRX
Royalty Pharma PLC Class ALsttxmvjdzBlhqyc$12.5 Bil
INCY
Incyte CorpXtbdvykPtytgy$11.6 Bil

Sponsor Center